Antibody Engineering & Therapeutics Europe, 2021
ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy
Keystone Symposia: Cancer Stem Cells, 2021
The Neuropilin-2 Targeting Antibody ATYR2810 Inhibits Non-Small Cell Lung Cancer Tumor Growth in Monotherapy and Combination Therapy
American Association for Cancer Research, 2021
A Domain-Specific Antibody to NRP2 Down-Regulated Epithelial-Mesenchymal Transition Genes and Enhanced Efficacy of Standard-of-Care Therapeutics for Aggressive Breast Cancer
American Association for Cancer Research, 2021
Neuropilin-2 is Expressed on Immune Cells Present in the Tumor Microenvironment, and May Contribute to the Suppression of Immune Regulation Leading to Progression and Metastasis of Cancer
Keystone Symposia: Tumor Metabolism and the Microenvironment, 2021
A Mass Spectrometry Proteomics-Based Approach to Identify Target Receptors for Novel Extracellular tRNA Synthetase Fragments
Society for Laboratory Automation and Screening, 2021
Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune Cells
American Thoracic Society, 2020
ATYR1923 Specifically Binds to Neuropilin-2, a Novel Therapeutic Target for the Treatment of Immune-Mediated Diseases
American Thoracic Society, 2020
Domain-Specific Antibodies to Neuropilin 2 Implicate VEGF-C and not Semaphorin 3F in Breast Cancer Stem Cell Function
American Association for Cancer Research, 2020
Isolation of monoclonal antibodies from anti-synthetase syndrome patients and affinity maturation by recombination of independent somatic variants
Berman, L; Chong, YE; Duncan, S; Klaus, A, Rauch K, Hamel K, Hervé K, Pfaffen S, Collins DW, Heyries K, Nangle L, Hansen C, King DJ.
mAbs 2020. 12:1,1836718